B and T cell prolymphocytic leukaemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• B-cell prolymphocytic leukaemia (B-PLL) and T-cell prolymphocytic leukaemia (T-PLL) are rare, aggressive hematologic malignancies.
• These disorders present a poor prognosis and require accurate diagnostic methods for differentiation.

Purpose of the Study:

• To differentiate B-PLL and T-PLL from each other and other lymphoid disorders using integrated diagnostic approaches.
• To explore the molecular pathogenesis of T-PLL and B-PLL to identify novel therapeutic targets.

Main Methods:

• Morphology, immunophenotyping, cytogenetics, and molecular diagnostics were employed.
• Analysis of mutations within the JAK-STAT pathway in T-PLL.
• Investigation of molecular abnormalities, including TP53 disruption, in B-PLL.

Main Results:

• Frequent mutations in the JAK-STAT pathway were identified in T-PLL, enhancing understanding of its pathogenesis.
• TP53 disruption was found to be a key molecular abnormality in B-PLL, associated with chemotherapy resistance.
• Alemtuzumab shows high response rates in T-PLL, but long-term remission often requires allogeneic stem cell transplant.

Conclusions:

• Accurate diagnosis of B-PLL and T-PLL relies on a combination of diagnostic techniques.
• Targeted therapies, such as B-cell receptor inhibitors for B-PLL and pathway inhibitors for T-PLL, are needed.
• Further research into the pathobiology of both leukaemias is crucial for developing effective treatment strategies and identifying new therapeutic targets.